Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 (a HER2-targeting ADC) in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study

Shangyi Rong

Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 (a HER2-targeting ADC) in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study

Academy of Pharmacy

Jiangsu Hengrui Pharmaceuticals Co., Ltd

Research output: Contribution to conference › Paper › peer-review

Original language	English
Publication status	Published - 18 Apr 2023
Event	American Association for Cancer Research - Duration: 14 Apr 2023 → 20 Apr 2023

Conference

Conference	American Association for Cancer Research
Period	14/04/23 → 20/04/23

Cite this

@conference{b2b8b5a73df048889d7b9ab42f15b8a8,

title = "Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 (a HER2-targeting ADC) in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study",

author = "Shangyi Rong",

year = "2023",

month = apr,

day = "18",

language = "English",

note = "American Association for Cancer Research ; Conference date: 14-04-2023 Through 20-04-2023",

}

TY - CONF

T1 - Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 (a HER2-targeting ADC) in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study

AU - Rong, Shangyi

PY - 2023/4/18

Y1 - 2023/4/18

M3 - Paper

T2 - American Association for Cancer Research

Y2 - 14 April 2023 through 20 April 2023

ER -